Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Vaccine. 2010 Jul 19;28(32):5179-84. doi: 10.1016/j.vaccine.2010.05.075. Epub 2010 Jun 15.
Intra-nasal administration of a recombinant adenovirus expressing Mycobacterium tuberculosis antigen 85A (Ad85A) has been shown to provide protection against challenge with M. tuberculosis. However the role of the upper respiratory tract associated lymphoid tissue, specifically the nasal associated lymphoid tissue (NALT), in providing protection has yet to be elucidated. Here we administered Ad85A to BALB/c mice alone or following BCG priming, using intranasal inocula targeting the whole respiratory tract or only the NALT, to show that Ad85A induces an immune response in the NALT insufficient to provide protection. Rather, Ad85A delivered through the respiratory tract must induce a deep lung immune response in order to protect against M. tuberculosis.
鼻腔内给予表达结核分枝杆菌抗原 85A（Ad85A）的重组腺病毒可提供针对结核分枝杆菌的保护。然而，上呼吸道相关淋巴组织（特别是鼻相关淋巴组织（NALT））在提供保护方面的作用尚未阐明。在这里，我们通过鼻腔接种，将 Ad85A 单独或在 BCG 接种后给予 BALB/c 小鼠，鼻腔接种的目标是整个呼吸道或仅 NALT，结果表明 Ad85A 在 NALT 中诱导的免疫反应不足以提供保护。相反，通过呼吸道给予的 Ad85A 必须诱导肺部深部免疫反应才能预防结核分枝杆菌。
